The new age of lab-grown psychedelics
The psychedelics industry is experiencing a surge in investment and regulatory easing, with potential therapeutic applications in mental health treatment. Companies are exploring microbial manufacturing to meet growing demand for psychedelic compounds.
The psychedelics industry is booming, with $2.5 billion invested between 2020 and 2021. US President Donald Trump's executive order to loosen restrictions on psychedelics-based mental health therapies sparked a 31% jump in shares of AtatiBeckley. Australia, the Netherlands, and Canada are also easing regulations, allowing psychedelic substances like psilocybin and MDMA for therapeutic use. Research has shown promise in using psychedelics to treat depression, with psilocybin found to be as effective as traditional antidepressants. However, the industry faces a potential supply shortfall due to high production costs and limited sustainable sources. Microbial manufacturing, using microbes to produce biological compounds, is being explored as a solution to meet growing demand.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.